- Home
- VIGL vs IFRX Comparison
VIGL vs IFRX Comparison
Compare VIGL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- IFRX
- Stock Information
- Founded
- VIGL 2020
- IFRX 2007
- Country
- VIGL United States
- IFRX Germany
- Employees
- VIGL N/A
- IFRX N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- IFRX Health Care
- Exchange
- VIGL Nasdaq
- IFRX Nasdaq
- Market Cap
- VIGL 134.9M
- IFRX 65.8M
- IPO Year
- VIGL 2022
- IFRX 2017
- Fundamental
- Price
- VIGL $7.96
- IFRX $0.79
- Analyst Decision
- VIGL Buy
- IFRX Strong Buy
- Analyst Count
- VIGL 7
- IFRX 4
- Target Price
- VIGL $8.00
- IFRX $7.75
- AVG Volume (30 Days)
- VIGL 1.5M
- IFRX 346.2K
- Earning Date
- VIGL 08-12-2025
- IFRX 08-07-2025
- Dividend Yield
- VIGL N/A
- IFRX N/A
- EPS Growth
- VIGL N/A
- IFRX N/A
- EPS
- VIGL N/A
- IFRX N/A
- Revenue
- VIGL N/A
- IFRX $140,242.00
- Revenue This Year
- VIGL N/A
- IFRX N/A
- Revenue Next Year
- VIGL N/A
- IFRX $6,309.47
- P/E Ratio
- VIGL N/A
- IFRX N/A
- Revenue Growth
- VIGL N/A
- IFRX 30.90
- 52 Week Low
- VIGL $1.31
- IFRX $0.71
- 52 Week High
- VIGL $7.96
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- VIGL 88.44
- IFRX 35.74
- Support Level
- VIGL $7.86
- IFRX $0.77
- Resistance Level
- VIGL $7.90
- IFRX $0.83
- Average True Range (ATR)
- VIGL 0.03
- IFRX 0.05
- MACD
- VIGL -0.20
- IFRX 0.02
- Stochastic Oscillator
- VIGL 91.67
- IFRX 35.40
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.